
    
      This cohort study will recruit chronic lymphocytic leukemia (CLL) patients who were treated
      with first and second-line Bendamustine plus Rituximab (BR) from January 2008 to December
      2014 from European centres adhering to the GIMEMA group and the ERIC group, and aims at
      observing the progression-free survival in CLL patients.
    
  